anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Our research is designed as a case-control study. 20 patients diagnosed with post-polio syndrome who present to the Istanbul Physical Medicine and Rehabilitation Training and Research Hospital clinics and 20 healthy volunteers will be included in the study. The sociodemographic data of patients and volunteers, such as age, gender, height, weight, body mass index, education level, and occupation, will be recorded. The age at which polio was contracted, the time elapsed since polio, and any accompanying illnesses will be documented. Additionally, if patients experience new symptoms such as pain, weakness, or fatigue, the severity of these symptoms will be assessed using the Visual Analog Scale. The frequency of falls and the presence of fractures caused by falls, ambulation method, and devices used will be noted. Muscle weakness in the extremities will be identified by applying the Manual Muscle Test through physical examination. Subsequently, the patient's current symptoms related to depression and anxiety will be evaluated using the Hospital Anxiety and Depression Scale (HADS), fatigue level will be assessed using the Fatigue Severity Scale (FSS), and quality of life will be evaluated using the Short Form-36 (SF-36).
A docking assembly for a point-of-care analyzer. The docking assembly comprises an adapter and interface clip. Adapter includes an adapter body attachable to the point-of-care analyzer, the adapter body having an opening and adapter electrical connector. The interface clip is receivable in the opening and includes a clip body and clip electrical connector. Clip electrical connector includes a clip interface member electrically interfaceable with a data and power port of a handheld computing device, and a clip data and power member configured to electrically connect with an adapter interface member. The adapter electrical connector and the clip electrical connector are configured to facilitate charging of the handheld computing device through an electrical connection between at least one adapter charging contact and the clip interface member. Adapters, interface clips, point-of-care assemblies using the docking assemblies, and methods of operating such point-of-care assemblies are provided, as are other aspects.
Motion sickness (MS) is a common physiological response that often occurs when individuals are exposed to environments with repeated acceleration stimuli. MS results from a mismatch between the vestibular system and visual and proprioceptive inputs. As a crucial organ for sensing acceleration stimuli, the vestibular system is closely related to the onset of MS. However, the complex pathogenesis of MS has led to its diagnosis primarily relying on subjective questionnaires, with a lack of objective indicators for evaluation. To identify objective indicators for evaluating MS, we conducted rotating chair stop experiments based on the principle of vestibulo-ocular reflex with 65 volunteers, obtaining their nystagmus slow-phase velocity and related time constants. Additionally, we conducted detailed MS questionnaires with these volunteers to assess their MS susceptibility. Through correlation analysis, we explored whether the nystagmus slow-phase velocity and related time constants significantly correlated with the MS questionnaire scores. The results showed significant positive correlations between the maximal nystagmus slow-phase velocity, cupula time constant, velocity storage time constant, and the nystagmus duration with the MS questionnaire scores in the 65 volunteers. These results indicated that these nystagmus parameters could serve as objective indicators for assessing MS susceptibility. Using K-Means clustering analysis, we classified MS susceptibility into categories I, II, III, and IV, and conducted K-Means clustering analysis on the corresponding nystagmus slow-phase velocity, cupula time constant, velocity storage time constant, and nystagmus duration. The magnitude and range of these indicators at different levels was quantified, offering objective and quantitative indicators for the clinical diagnosis of MS.
Home care workers (HCW)HCWs in the VR/AR group received 2.5 hours of VR and AR training. VR offered learners the standard oral care procedures under different physical and oral health conditions in elderly people and AR simulation training for the manual Bass brushing technique.
A two-container dispenser for storing, mixing and dispensing hair dye for touch up applications. The dispenser retains and separates two hair dye components until they are to be mixed immediately prior to application of the dye. The two containers are permanently secured together via a valve assembly. When the valve assembly is in a closed position, the interior chambers and therefore the contents of the containers remain separated. When the valve assembly is opened by rotating one of the containers through 180 degrees, the two interior chambers are in fluid communication and the contents can flow between the containers to form a hair dye mixture. The connections between the first and second containers and the valve assembly are such that all three remain secured together when the valve assembly is moved between the closed and open positions.
The prepn. of antidiarrhoeal substance (I) comprises: (1) enzymatic hydrolysis of a mixt. of powdered cereal and leguminous grains in an aq. medium, leading to at least partial decomposition of its carbohydrates and proteins into oligosaccharides, polypeptides and aminoacids; and (2) recovery from the hydrolysis medium of the mixt. obtd. in the form a dry powder by spray drying. More specifically, the cereal grain is Oriza sativa (rice). The leguminous seed is Phaseolus mungo (mung bean). The ratio of Oriza sativa/Phaseolus mungo in the starting mixt. is 1.8-2.2/1. Hydrolysis pref. takes place in the presence of alpha-amylase. USE - (I) is an antidiarrhoeal, having beneficial effects on intestinal activity, and partic. on sodium transport. An appropriate dosing regimen consists of two tablets contg. 1 g each of (I), taken every two or three hrs. according to the severity of diarrhoea
Foscarnet Sodium Injection is administered by controlled intravenous infusion, either by using a central venous line or by using a peripheral vein. The rate of infusion must be no more than 1 mg/kg/minute. An individualized dose of Foscarnet Sodium Injection should be calculated on the basis of body weight (mg/kg), renal function, indication of use and dosing frequency (refer to DOSAGE subsection). To reduce the risk of nephrotoxicity, creatinine clearance (mL/min/kg) should be calculated even if serum creatinine is within the normal range, and doses should be adjusted accordingly.

An individualized dose at the required concentration (24 mg per mL or 12 mg per mL) for the route of administration (central line or peripheral line) needs to be aseptically prepared prior to dispensing. The standard 24 mg per mL solution may be used with or without dilution when using a central venous catheter for infusion. When a peripheral vein catheter is used, the 24 mg per mL injection must be diluted to a 12 mg per mL concentration with 5% dextrose in water or with a normal saline solution prior to administration to avoid local irritation of peripheral veins. Dilutions and/or removals of excess quantities should be accomplished under aseptic conditions. Solutions thus prepared should be used within 24 hours of first entry into a sealed bottle.
1. A method for preparing a solution for nasal spray comprising one or several sex hormones and a cyclodextrin, characterized in that  the cyclodextrin is dissolved in a purified water to a concentration from 100 to 1000 mg/ml, the hormone(s) are added to the solution when heating from 40 to 90 degree C, the purified water is added to obtain the required concentration of hormone(s) either directly or after lyophilisation of the obtained solution. 2. The method according to claim 1, characterized in that the cyclodextrin is dissolved in the purified water in a concentration from 400 to 500 mg/ml and the hormone(s) are added at a temperature from 70 to 90 degree C. 3. The method according to claim 1 or 2, characterized in that the cyclodextrin is a partially  methylated cyclodextrin. 4. The method according to claim 3, characterized in that the cyclodextrin is a random partially methylated cyclodextrin. 5. The method according to any of claims 1 to 4, characterized in that the sex hormone is estradiol. 6. The method according to any of claims 1 to 4, characterized in that the sex hormone is estradiol and/or progestogen. 7. The method according to claim 6, characterized in that the progestogen is a 19-nortestosterone derivative. 8. The method according to claim 7, characterized in that the progestogen is a 19-nortestosterone acetate. 9. The method according to any of claims 1 to 4, characterized in that the sex hormone is testosterone. 10. The method according to any of claims 1 to 5, characterized in that the aqueous solution is prepared using partially methylated β-cyclodextrin in a concentration 400-500 mg/ml, when agitating estradiol is added and the solution is maintained at 80 degree C, the purified water is added to bring the volume for obtaining the final estradiol concentration of about 2,14 mg/ml. 11. The method according to claim 10, characterized in that the solution comprises also sodium chloride and its pH value is up to 6.
The invention relates to a preparation method for a traditional Chinese medicine lotion for treatment of confusing-type closed fractures, and belongs to the technical field of traditional Chinese medicine preparation methods. At present, treatment of confusing-type closed fractures generally uses western medicines. A disadvantage of using western medicines is that certain side effects exist. The technical solution of the invention includes: taking glossy ganoderma, ginseng root, human milk, Chinese date, Chinese yam, black-bone silky fowl, stem and leaf of cabbage, dried longan prlp, largehead atractylodes rhizome, american ginseng, lotus seed, root of pilose asiabell, sharpleaf galangal fruit, radix astragali, manyflower solomonseal rhizome, rice, dried ginger, rohdea japonica root, salt alkali, common lantana leaf, herb of common stonecrop, leaf and twig of fruticose breynia, hastate phymatopsis herb with root, China ixeris, medicinal changium root, loveyly hemsleya root, common anemarrhena rhizome, arrowshaped tinospora root, Chinese globeflower flower, honeysuckle flower, spanishneedles herb, heartleaf houttuymia herb, crneate lespedeza, common st.john's wort herb, herba sedi, underleaf pearl, donkey-hide gelatin, and liquorice root; soaking the above 38 traditional Chinese medicines in water; decocting by slow fire; and filtering to remove dregs. The left medicine liquid is the traditional Chinese medicine lotion for the treatment of confusing-type closed fractures. The lotion has the advantages that the traditional Chinese medicine liquid is fewer in side effects, short in treatment courses, and high in cure rate.
This is an adult and pediatric prospective, longitudinal study in which we will measure symptoms, QOL and inflammation at baseline and again at 2, 4 and 6 weeks after starting stand of care (SOC) four food elimination diet (FFED) (Aim 1). Newly or previously diagnosed patients with EoE with active disease who will be undergoing SOC FFED will be offered entry into the study by the PI's or their local co-investigators at each of their institutions. EoE patients who are in remission on SOC FFED from Aim 1 will be recruited to participate in this food reintroduction trial in Aim 2. Eligible subjects will undergo SOC sequential food reintroductions and during the food introduction, ESTs will be performed at 2 and 4 week intervals during a clinic visit. If inflammation is detected by the EST, this food will be eliminated from the diet for six weeks and a repeat EST will be administered at this time to assess inflammation. If inflammation has resolved based on EST results, food reintroduction will resume. If no inflammation is detected by the EST at the 4 week interval, a new food will be added. EST will be performed after each food reintroduction as outlined above. Based on known allergenic properties of these foods, the order of food reintroduction will be soy, eggs, wheat and milk.
Each subject will be treated a single time at 4mm, 5mm and 7 mm depths at a minimum of 3 treatment areas. A non-treated control area will also be designated. Histology evaluations for all treatment areas and the control area will occur 30 days after treatment (Day 30).
Participants who were originally randomized to the placebo group in the 01-9001 and/or the 01-9001E studies received glatiramer acetate 20 milligrams (mg) subcutaneous (SC) injection daily at the start of this study. After 18 July 2014 (protocol amendment 12), participants were offered the opportunity to continue treatment with glatiramer acetate 20 mg daily or switch to glatiramer acetate 40 mg three times weekly (TIW). The treatment continued for up to 288 months.
If you have questions or problems, talk with your doctor or other healthcare provider. You can ask your doctor or pharmacist for the information about metformin that is written for health care professionals. Medicines are sometimes prescribed for purposes other than those listed in a patient information leaflet. Do not use metformin for a condition for which it was not prescribed. Do not share your medicine with other people.

CARACO PHARMACEUTICAL LABORATORIES, LTD.

Manufactured by: Sun Pharmaceutical Ind. Ltd. Halol-Baroda Highway, Halol-389 350, Gujarat, India. Distributed by: Caraco Pharmaceutical Laboratories, Ltd. 1150 Elijah McCoy Drive, C.S. No: 5249T34 Detroit, MI 48202 Iss.3/10
All patients will start with perifosine at bedtime daily and Bortezomib IV on days 1, 4, 8, and 11 q 21 days. Patients will be evaluated at q 3 weeks. If the patient has a CR, PR, MR or stable disease, they will continue treatment.
Patients newly diagnosed with portal hypertension and starting treatment with non-selective β-blockers will be monitored with SHAPE Three vials with 48 µl of Sonazoid (GE Healthcare, Oslo, Norway) microbubbles (6 ml) will be prepared and drawn into a 10 ml syringe, placed in a syringe pump. Sonazoid will be co-infused at a rate of 0.024 µl/kg body weight/minute (suspension infusion rate of 0.18 ml/kg/hour) together with a 0.9% NaCl solution infused at a rate of at least 2 ml/min.
In this study, the intervention design part of the researchers referred to Greg Glassman's (2010) "CrossFit training guide" and designed a high-intensity functional training program based on the characteristics of wushu routines . This study employs a Cluster Randomized Controlled Trial (CRCT) design. The experimental period of this study is 12 weeks, three times per week. The training lasts 1.5 hours, including one hour of physical fitness training and half an hour of specialized technical training. The sample for this study is male Wushu routine athletes from the Hebei Institute of Physical Education and Hebei Normal University, with 60 participants. Athletes were randomly assigned to two different training locations and divided into experimental and control groups. The specialized skills training content of the two groups is the same, with the only difference being the physical training part. The experimental group received high-intensity functional training, while the control group maintained routine training. In addition, the specific content of routine training for the control group is the school's standard training plan. The dependent variables to be measured in this study are physical fitness (strength, power, speed, endurance, and flexibility) and jumping difficulty movements (Flying Kick, Whirl Wind Kick, Outward Leg Swing in Flight, and Side Somersaults). This study measured the dependent variable three times throughout the intervention: baseline before the experimental intervention, post-test 1 after 6 weeks, and post-test 2 after 12 weeks. Finally, statistical analysis was conducted on the three test results.
The invention relates to an active part of a traditional Chinese medicine composite for curing diabetes. The active part is prepared from root-bark of Chinese wolfberry, ramulus euonymi, coptis chinensis and dogwood according to weight proportion. A preparation method of the actively part comprises the following steps: weighing all the medicinal materials of a prescription; decocting the medicinal materials with water with an amount which is 5 times of that of the medicinal materials; filtering; remaining filtrate; adding water with an amount which is 5 times of that of decoction dregs into the decoction dregs; decocting; filtering; combining filtrates obtained from the two times of decocting; depressurize and concentrating the combined filtrate; applying concentrated liquid on a macroporous resin column for purpose of enrichment; eluting by using ethanol with a certain concentration; collecting eluent; depressurizing and recovering solvent; concentrating the solvent to a density of 3 g of crude drug per milliliter; and obtaining the active part of the traditional Chinese medicine composite for curing diabetes. In the invention, a theory of traditional Chinese medical science is followed, namely three heats (i.e. dryness-heat, moist heat and stagnant heat) are symptoms and deficiency of qi and yin as well as hepatic and renal deficiency is as root cause, wherein the symptoms and the root causes interact as both causes and effects. The active part of the traditional Chinese medicine composite for curing diabetes on a basis of a three-heat theory is obtained. As being demonstrated by pharmacologic tests, the active part in small dosage can obviously reduce blood sugar content of a model mouse, and can achieve extremely obvious reduction of the blood sugar content of the model mouse in medium/high dosage.
Portable multifunctional device designed for sanitizing of inner and outer surfaces of shoes, sanitizing of air, water, household items and surfaces, treatment of skin and wound infection, nails fungus, cosmetic use, and detection of counterfeit currency. The device is able to perform all the above sanitizing, therapeutic and cosmetic functions that would otherwise be carried out by various different devices. The enhance functionality has been accomplished without alteration of any parts of the device. Apparatus utilizes light radiation in three diapasons: 100-280, 405-495, and 700-1064 nm and provides distant sanitizing. Apparatus comprises at least one module with a dual DC-AC power supply. Each module has a germicidal unit, retractable flexible shaft, shade, and housing. The flexible shaft allows positioning the germicidal units under different angle for uniform distant illumination. The device is suitable for household, traveling, and military use.
Mild Cognitive Impairment (MCI) can be defined as a pre-dementia symptom and, when associated with aging, characterizes individuals with cognitive decline below the level of dementia. This decline, which can begin as early as 45 years of age, leads to impairments in memory, learning, language, orientation, and executive functions, which are more visible from the sixth decade of life onwards, with a risk of reduced autonomy and independence, and is seen by researchers as the first stage of a process of loss. This loss is progressive, lasting several years and resulting in MCI, characterized by objective cognitive loss, which does not yet compromise autonomy but has a conversion rate to dementia of 10% per year. Cognitive decline can be accompanied by increased depressive symptoms and decreased functional capacity and is related to inflammatory conditions, described in the literature as "inflammaging". Studies with beat stimulation have shown benefits in different important outcomes of cognitive function and depression. Thus, audiovisual neurostimulation (AVNS) is a possible non-pharmacological treatment that might have a direct influence on the brain wave patterns, altered in MCI and depression, modulating these specific wave frequencies to functional patterns similar to those found in healthy individuals. Having this, it can also influence agility and functional balance and reduce chronic inflammatory conditions.
BACKGROUND: Menstrual irregularities are present in >30% of women with type 1 diabetes mellitus (T1DM). These abnormalities will likely lead to reduced fertility and earlier menopause. T1DM management has changed over time, with even more emphasis on stringent levels of glycemic management. Thus, we investigated whether therapeutic T1DM changes have an influence on the proportion of menstrual disorders in women with T1DM.
METHODS: A meta-analysis was performed that included clinical trials in which menstrual abnormalities in women with T1DM were studied. The literature was checked for studies in which women with T1DM were compared with healthy, age-matched controls. Case-control, cohort, and cross-sectional studies were included. The primary endpoint was rate of menstrual dysfunction.
RESULTS: Menstrual dysfunction was higher in women with T1DM compared with controls (odds ratio 2.08, 95% confidence interval [CI] 1.43 to 3.03, p<0.001), even when sensitivity analysis was performed, considering only studies published after 2000. The age at menarche was higher for women with T1DM compared with controls (mean difference 0.53, 95% CI 0.32 to 0.74 years, p<0.001). The proportion of menstrual abnormalities in T1DM was inversely related to diabetes duration, but was unrelated to both body mass index and glycated hemoglobin.
CONCLUSIONS: The meta-analytic approach used confirmed the correlation between T1DM and menstrual irregularities. T1DM menstrual dysfunction seemed unrelated to change in therapeutic management across years, as well as to glycemic management and body weight. The underlying pathogenetic mechanisms are not fully understood.
Participants with traumatic brain injury (TBI) that are enrolled in a comprehensive rehabilitation program (R) will be engaged in an aerobic exercise program (AER). These participants will also receive standard rehabilitation which includes exercise within the physical therapy session. Given that the duration of the rehabilitative program is variable the period of AER training will be no less than 4 weeks and will not exceed 30 weeks. Activity levels will be monitored.
Members of the American Society of Retinal specialists, the American Uveitis Society and the International Uveitis Society were invited to contribute their consecutive cases of ION not responding to standard therapy (corticosteroids (CST) 4 or immunosuppression) and treated with intravitreal anti-VEGF agents. Cases with concomitant or prior cystoid macular edema, diabetes mellitus, or age-related macular degeneration were excluded. Most of the patients had initially been treated in a stepwise fashion with high doses of oral CST, with or without intraocular or subtenon CST or immunosuppressive therapy (as monitored by a rheumatologist). All patients opted to intravitreal anti-VEGF treatment after detailed information about the limited experience, potential side effects and the off-label character of the drug. The risks and benefits of intravitreal therapy were discussed with the patients (or their guardians) who signed an informed consent. Primary outcome measure: Best corrected visual acuity measured as logMAR. Secondary outcome measures:macular thickness on OCT, and stoppage of leakage by IVFA.